Publication:
Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia 5-Year SAFEHEART Registry Follow-Up

dc.contributor.authorPerez-de-Isla, Leopoldo
dc.contributor.authorAlonso, Rodrigo
dc.contributor.authorWatts, Gerald F.
dc.contributor.authorMata, Nelva
dc.contributor.authorSaltijeral-Cerezo, Adriana
dc.contributor.authorMuniz, Ovidio
dc.contributor.authorFuentes, Francisco
dc.contributor.authorDiaz-Diaz, Jose Luis
dc.contributor.authorde-Andres, Raimundo
dc.contributor.authorZambon, Daniel
dc.contributor.authorRubio-Marin, Patricia
dc.contributor.authorBarba-Romero, Miguel A.
dc.contributor.authorSaenz, Pedro
dc.contributor.authorSanchez-Munoz-Torrero, Juan F.
dc.contributor.authorMartinez-Faedo, Ceferino
dc.contributor.authorMiramontes-Gonzalez, Jose P.
dc.contributor.authorBadimon, Lina
dc.contributor.authorMata, Pedro
dc.contributor.authoraffiliation[Perez de Isla, Leopoldo] Hosp Clin San Carlos, IDISSC, Dept Cardiol, Madrid, Spain
dc.contributor.authoraffiliation[Perez de Isla, Leopoldo] Fdn Hipercolesterolemia Familiar, C Gen Alvarez Castro 14, Madrid 28010, Spain
dc.contributor.authoraffiliation[Alonso, Rodrigo] Fdn Hipercolesterolemia Familiar, C Gen Alvarez Castro 14, Madrid 28010, Spain
dc.contributor.authoraffiliation[Mata, Nelva] Fdn Hipercolesterolemia Familiar, C Gen Alvarez Castro 14, Madrid 28010, Spain
dc.contributor.authoraffiliation[Saltijeral Cerezo, Adriana] Fdn Hipercolesterolemia Familiar, C Gen Alvarez Castro 14, Madrid 28010, Spain
dc.contributor.authoraffiliation[Mata, Pedro] Fdn Hipercolesterolemia Familiar, C Gen Alvarez Castro 14, Madrid 28010, Spain
dc.contributor.authoraffiliation[Alonso, Rodrigo] Clin Las Condes, Santiago, Chile
dc.contributor.authoraffiliation[Watts, Gerald F.] Royal Perth Hosp, Ctr Cardiovasc Med, Lipid Disorders Clin, Perth, WA 6001, Australia
dc.contributor.authoraffiliation[Watts, Gerald F.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia
dc.contributor.authoraffiliation[Mata, Nelva] Madrid Hlth Author, Dept Epidemiol, Madrid, Spain
dc.contributor.authoraffiliation[Saltijeral Cerezo, Adriana] Hosp Tajo, Dept Cardiol, Madrid, Spain
dc.contributor.authoraffiliation[Muniz, Ovidio] Hosp Virgen Rocio, Dept Internal Med, Seville, Spain
dc.contributor.authoraffiliation[Fuentes, Francisco] Univ Hosp, Dept Internal Med, Cordoba, Spain
dc.contributor.authoraffiliation[Luis Diaz-Diaz, Jose] Hosp Abente & Lago, Dept Internal Med, La Coruna, Spain
dc.contributor.authoraffiliation[de Andres, Raimundo] Fdn Jimenez Diaz, Dept Internal Med, E-28040 Madrid, Spain
dc.contributor.authoraffiliation[Zambon, Daniel] Hosp Clin Barcelona, Dept Endocrinol, Barcelona, Spain
dc.contributor.authoraffiliation[Rubio-Marin, Patricia] Hosp SAS Jerez Frontera, Dept Internal Med, Cadiz, Spain
dc.contributor.authoraffiliation[Barba-Romero, Miguel A.] Complejo Hosp Univ, Dept Internal Med, Albacete, Spain
dc.contributor.authoraffiliation[Saenz, Pedro] Hosp Merida, Dept Internal Med, Extremadura, Spain
dc.contributor.authoraffiliation[Sanchez Munoz-Torrero, Juan F.] Hosp San Pedro Alcantara, Dept Internal Med, Caceres, Spain
dc.contributor.authoraffiliation[Martinez-Faedo, Ceferino] Cent Hosp, Dept Endocrinol, Asturias, Spain
dc.contributor.authoraffiliation[Miramontes-Gonzalez, Jose P.] Univ Hosp, Dept Internal Med, Salamanca, Spain
dc.contributor.authoraffiliation[Badimon, Lina] IIB St Pau, Inst Catalan Ciencias Cardiovasc, Barcelona, Spain
dc.contributor.funderFundacion Hipercolesterolemia Familiar
dc.contributor.funderInstituto de Salud Carlos III (ISCIII)
dc.contributor.funderCentro Nacional de Investigacion Cardiovascular (CNIC)
dc.contributor.funderMerck Sharp Dohme
dc.contributor.funderAstraZeneca
dc.contributor.funderAMGEN
dc.contributor.funderAEGERION
dc.contributor.funderISIS
dc.contributor.funderSanofi
dc.contributor.groupSAFEHEART Investigators
dc.date.accessioned2023-02-12T02:20:54Z
dc.date.available2023-02-12T02:20:54Z
dc.date.issued2016-01-05
dc.description.abstractBACKGROUND Familial hypercholesterolemia (FH) is the most common genetic disorder associated with premature atherosclerotic cardiovascular disease (ASCVD). There are sparse data on attainment of treatment targets; large registries that reflect real-life clinical practice can uniquely provide this information.OBJECTIVES We sought to evaluate the achievement of low-density lipoprotein cholesterol (LDL-C) treatment goals in FH patients enrolled in a large national registry.METHODS The SAFEHEART study (Spanish Familial Hypercholesterolemia Cohort Study) is a large, ongoing registry of molecularly defined patients with heterozygous FH treated in Spain. The attainment of guideline-recommended plasma LDL-C goals at entry and follow-up was investigated in relation to use of lipid-lowering therapy (LLT).RESULTS The study recruited 4,132 individuals (3,745 of whom were >= 18 years of age); 2,752 of those enrolled were molecularly diagnosed FH cases. Mean follow-up was 5.1 +/- 3.1 years; 71.8% of FH cases were on maximal LLT, and an LDL-C treatment target = 18 years of age); 2,752 of those enrolled were molecularly diagnosed FH cases. Mean follow-up was 5.1 +/- 3.1 years; 71.8% of FH cases were on maximal LLT, and an LDL-C treatment target <100 mg/dl was reached by only 11.2% of patients. At follow-up, there was a significant increasein the use of ezetimibe, drug combinations with statins, and maximal LLT. The presence of type 2 diabetes mellitus, adefective allele mutation, ezetimibe use, and the absence of previous ASCVD were predictors of the attainment ofLDL-C goals. CONCLUSIONS Despite the use of intensified LLT, many FH patients continue to experience high plasma LDL-C levelsand, consequently, do not achieve recommended treatment targets. Type of LDL-receptor mutation, use of ezetimibe,coexistent diabetes, and ASCVD status can bear significantly on the likelihood of attaining LDL-C treatment goals.
dc.description.versionSi
dc.identifier.citationPerez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muñiz O, et al. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. J Am Coll Cardiol. 2016 Mar 22;67(11):1278-85
dc.identifier.doi10.1016/j.jacc.2016.01.008
dc.identifier.essn1558-3597
dc.identifier.issn0735-1097
dc.identifier.urihttp://hdl.handle.net/10668/18806
dc.identifier.wosID371881400003
dc.issue.number11
dc.journal.titleJournal of the american college of cardiology
dc.journal.titleabbreviationJ. am. coll. cardiol.
dc.language.isoen
dc.organizationÁrea de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
dc.organizationHospital Universitario Reina Sofía
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationAGS - Jerez, Costa Noroeste y Sierra de Cáidz
dc.page.number1278-1285
dc.provenanceRealizada la curación de contenido 16/06/2025
dc.publisherElsevier
dc.relation.publisherversionhttps://linkinghub.elsevier.com/retrieve/pii/S0735-1097(16)00229-1
dc.rights.accessRightsRestricted Access
dc.subjectGuidance
dc.subjectManagement
dc.subjectEzetimibe
dc.subjectMortality
dc.subjectEfficacy
dc.subjectTherapy
dc.subjectDisease
dc.subjectCohort
dc.subjectRisk
dc.subjectCare
dc.subjectÁrea de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
dc.subjectCardiovascular disease
dc.subjectLDL-receptor mutations
dc.subjectLipid-lowering therapy
dc.subjectLow-density lipoprotein cholesterol
dc.subject.decsHipercolesterolemia familiar
dc.subject.decsColesterol LDL
dc.subject.decsEnfermedad cardiovascular aterosclerótica
dc.subject.decsTerapia hipolipemiante
dc.subject.decsEzetimiba
dc.subject.decsDiabetes mellitus tipo 2
dc.titleAttainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia 5-Year SAFEHEART Registry Follow-Up
dc.typeresearch article
dc.volume.number67
dc.wostypeArticle
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format